Multiple vaccination including serogroup C meningococcus
Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminum phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae ; and (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.
1. A kit, comprising a first immunogenic component and a second immunogenic component, wherein: (a) the first immunogenic component comprises a conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C; and (b) the second immunogenic component comprises an acellular Bordetella pertussis antigen and an inactivated poliovirus antigen; wherein the kit does not comprise a lyophilized conjugated H. influenzae type b antigen.
2. The kit of claim 1 , wherein the OAc+ strain is of serotype 16.
3. The kit of claim 1 , wherein the OAc+ strain is of serosubtype P1.7a,1 or serosubtype P1.1.
4. The kit of claim 1 , wherein the OAc+ strain is C11.
5. The kit of any one of claims 1 to 4 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is conjugated to a CRM197 carrier protein, a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein or a Haemophilus influenzae protein D carrier protein.
6. The kit of claim 1 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a full length saccharide.
7. The kit of claim 1 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a fragment of a full length saccharide.
8. The kit of claim 7 , wherein the capsular saccharide has a molecular weight of <100 kDa.
9. The kit of claim 7 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
10. The kit of claim 1 , wherein the capsular saccharide has a molecular weight of <100 kDa.
11. The kit of claim 10 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
12. The kit of claim 1 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate has a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
13. The kit of claim 1 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate is present at between 1 μg and 20 μg (measured as saccharide) per dose.
14. The kit of claim 1 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C is not adsorbed to an aluminium salt.
15. The kit of claim 1 , wherein the acellular Bordetella pertussis antigen comprises one, two or three of the following antigens: (1) detoxified pertussis toxin (PT); (2) filamentous hemagglutinin (FHA); (3) pertactin.
16. The kit of claim 15 , wherein PT, FHA and pertactin are adsorbed to aluminium hydroxide.
17. The kit of claim 1 , wherein the inactivated poliovirus antigen is from poliovirus Type 1, poliovirus Type 2 and poliovirus Type 3.
18. A kit, comprising a first immunogenic component, a second immunogenic component and a third immunogenic component, wherein: (a) the first immunogenic component comprises a conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C; (b) the second immunogenic component comprises an acellular Bordetella pertussis antigen and/or an inactivated poliovirus antigen; and (c) the third immunogenic component comprises a conjugated capsular saccharide from Streptococcus pneumoniae ; wherein the kit does not comprise a lyophilized conjugated H. influenzae type b antigen.
19. The kit of claim 18 , wherein the OAc+ strain is of serotype 16.
20. The kit of claim 18 , wherein the OAc+ strain is of serosubtype P1.7a,1 or serosubtype P1.1.
21. The kit of claim 18 , wherein the OAc+ strain is C11.
22. The kit of any one of claims 18 to 21 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is conjugated to a CRM197 carrier protein, a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein or a Haemophilus influenzae protein D carrier protein.
23. The kit of claim 18 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a full length saccharide.
24. The kit of claim 18 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a fragment of a full length saccharide.
25. The kit of claim 24 , wherein the capsular saccharide has a molecular weight of <100 kDa.
26. The kit of claim 24 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
27. The kit of claim 18 , wherein the capsular saccharide has a molecular weight of <100 kDa.
28. The kit of claim 27 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
29. The kit of claim 18 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate has a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
30. The kit of claim 18 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate is present at between 1 μg and 20 μg (measured as saccharide) per dose.
31. The kit of claim 18 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C is not adsorbed to an aluminium salt.
32. The kit of claim 18 , wherein the acellular Bordetella pertussis antigen comprises one, two or three of the following antigens: (1) detoxified pertussis toxin (PT); (2) filamentous hemagglutinin (FHA); (3) pertactin.
33. The kit of claim 32 , wherein PT, FHA and pertactin are adsorbed to aluminium hydroxide.
34. The kit of claim 18 , wherein the inactivated poliovirus antigen is from poliovirus Type 1, poliovirus Type 2 and poliovirus Type 3.
35. The kit of claim 18 , wherein the third immunogenic component comprises capsular saccharides from more than one serotype of Streptococcus pneumoniae.
36. The kit of claim 18 , wherein the third immunogenic component comprises capsular saccharides for at least Streptococcus pneumoniae serotypes 6B, 14, 19F and 23F.
37. The kit of claim 35 , wherein the Streptococcus pneumoniae are conjugated to a carrier protein selected from the group consisting of: CRM197, tetanus toxoid, diphtheria toxoid and Haemophilus influenzae protein D.
38. The kit of claim 36 , wherein the Streptococcus pneumoniae are conjugated to a carrier protein selected from the group consisting of: CRM197, tetanus toxoid, diphtheria toxoid and Haemophilus influenzae protein D.
39. The kit of claim 35 , wherein the conjugated capsular saccharides from Streptococcus pneumonia conjugate each have a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
40. The kit of claim 35 , wherein the conjugated capsular saccharides from Streptococcus pneumoniae are each present at between 1 μg and 20 μg (measured as saccharide) per dose.
41. An immunogenic composition comprising a conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C, an acellular Bordetella pertussis antigen and an inactivated poliovirus antigen; wherein the composition does not comprise a lyophilized conjugated H. influenzae type b antigen.
42. The immunogenic composition of claim 41 , wherein the OAc+ strain is of serotype 16.
43. The immunogenic composition of claim 41 , wherein the OAc+ strain is of serosubtype P1.7a,1 or serosubtype P1.1.
44. The immunogenic composition of claim 41 , wherein the OAc+ strain is C11.
45. The immunogenic composition of any one of claims 41 to 44 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is conjugated to a CRM197 carrier protein, a tetanus toxoid carrier protein, a diphtheria toxoid carrier protein or a Haemophilus influenzae protein D carrier protein.
46. The immunogenic composition of claim 41 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a full length saccharide.
47. The immunogenic composition of claim 41 , wherein the capsular saccharide from OAc+ strain of Neisseria meningitidis serogroup C is a fragment of a full length saccharide.
48. The immunogenic composition of claim 47 , wherein the capsular saccharide has a molecular weight of <100 kDa.
49. The immunogenic composition of claim 47 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
50. The immunogenic composition of claim 41 , wherein the capsular saccharide has a molecular weight of <100 kDa.
51. The immunogenic composition of claim 50 , wherein the capsular saccharide has a molecular weight of between 5 kDa-75 kDa.
52. The immunogenic composition of claim 41 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate has a saccharide:protein ratio (w/w) of between 1:10 and 10:1.
53. The immunogenic composition of claim 41 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C conjugate is present at between 1 μg and 20 μg (measured as saccharide) per dose.
54. The immunogenic composition of claim 41 , wherein the conjugated capsular saccharide from a OAc+ strain of Neisseria meningitidis serogroup C is not adsorbed to an aluminium salt.
55. The immunogenic composition of claim 41 , wherein the acellular Bordetella pertussis antigen comprises one, two or three of the following antigens: (1) detoxified pertussis toxin (PT); (2) filamentous hemagglutinin (FHA); (3) pertactin.
56. The immunogenic composition of claim 55 , wherein PT, FHA and pertactin are adsorbed to aluminium hydroxide.
57. The immunogenic composition of claim 41 , wherein the inactivated poliovirus antigen is from poliovirus Type 1, poliovirus Type 2 and poliovirus Type 3.